Corporate Presentation

September 2015

Safe Harbor statement Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms. All statements other than statements of historical facts included in this presentation regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results, anticipated results of our sales and marketing efforts, expectations concerning payer reimbursement and the anticipated results of our product development efforts. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully and profitably market our products; the acceptance of our products by patients and health care providers; the amount and nature of competition from other cancer screening products and procedures; our ability to maintain regulatory approvals and comply with applicable regulations; our success establishing and maintaining collaborative and licensing arrangements; our ability to successfully develop new products; and the other risks and uncertainties described in the Risk Factors and in the Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Report(s) on Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. We have filed a registration statement, including a prospectus, with the U.S. Securities and Exchange Commission (the “SEC”) for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, the issuer, any underwriter, or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling 877-547-6340 or 800-792-2413. 2

To work with patients, payers and providers to help play a role in the

eradication of colorectal cancer

OUR FIRST MISSION

3

Source: ACS Cancer Facts & Figures 2015; all figures annual

Colon cancer: America’s second most lethal cancer

new diagnoses in 2015

15,590 27,540

40,560 40,730 [VALUE]

158,040

Esophageal Prostate Pancreas Breast Colorectal Lung

Annual US cancer mortality

132,700

deaths in 2015 49,700

4

132,700 new diagnoses in US

5 Sources: J Natl Cancer Inst. 2009; 101:1225-1227 (Itzkowitz) N Engl J Med 2012;366:687-96 (Zauber); Gastro 1997;112:594-692 (Winawer)

Why is colon cancer the “Most preventable, yet least prevented form of cancer”?

Pre-cancerous polyp Four stages of colon cancer

10+

years

6 Source: Winawer SJ et al. N Engl J Med. 1993; 329(27):1977-1981 Zauber AG et al. N Engl J Med. 2012; 366(8): 687-696.

Colorectal cancer screening works

Incidence reduced by

90% over 7 years versus expected outcome

Mortality reduced by

60% over 22 years versus

national average

7 Source: SEER 18 2004-2010

Detecting colorectal cancer early is important

9 out of 10 Survive 5 years if

Diagnosed in Stages I or II

1 out of 10 Survive 5 years if

Diagnosed in Stage IV

Source: CDC MMWR 2013; 64(17);464-468 (Sabatino)

But many Americans aren’t getting screened

42%

of Americans not current on colon cancer screening

8

Source: J Natl Cancer Inst. 2011; 103:1-12 (Mariotto)

Rising cost of colorectal cancer treatment

2010 2015 2020

Projected annual treatment costs

in 2020

$20B

$14B

9

Cologuard®: Foundation to our success

§  FDA-approved & Medicare-covered

§  Developed in collaboration with Mayo Clinic

§  New England Journal of Medicine results:

•  92% cancer sensitivity (all stages)

•  69% high grade dysplasia sensitivity

•  87% specificity

•  94% sensitivity for stages I to II cancer

§  Included in American Cancer Society guidelines

Source: American Cancer Society Cancer Facts & Figures 2015. Atlanta: American Cancer Society; 2015. 10

160

High-quality sales force driving Cologuard® demand

200

Sales Team on June 1

Creating a results-driven field force

§  Strategically aligned co-promotion partner

§  Average 10-years sales experience

§  Focused on high-value physicians §  Real-time data guides strategy

11

12

World-class lab delivering results

Capable of processing more than 1 million Cologuard® tests per year

Cologuard’s® strong demand and launch trajectory

4K 11K

21K

>32K

Q4 Q1 Q2 Q3

13

Completed Cologuard Tests

Guidance

80,000 Cologuard orders through Q2

Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun

Physicians ordering Cologuard® is rapidly expanding

14,700 ordering physicians

Adding ~500 new physicians weekly

14

Sources: US Census, “Health Insurance Coverage Status and Type of Coverage by Selected Characteristics: 2013” US Census, “State Characteristics: Vintage 2013” AIS Directory of Health Plans: 2015 Exact Sciences internal analysis *market share for individuals ages 50-64

Reimbursement landscape for insured patients 50+ years of age

Medicare 46%

Commercial Coverage for Cologuard®

9%*

Pursuing Coverage

45%

15

Growth strategy to expand coverage and contracting

Quality of Care

Cost Savings

Member Satisfaction

Compelling payer value proposition

16

NEJM publication – 92% sensitive, Medicare NCD

Easy, non-invasive test; >70% patient compliance

Cologuard® delivering positive budget impact

USPSTF guidelines promote Cologuard® use, expand coverage

§ Draft guidelines expected 2015 § Final rating expected 2016

17

Included in HEDIS &

STARS quality metrics

Commercial insurers follow

USPSTF Strong incentives for providers and payers to promote

Cologuard

18 *Patient compliance rate: number of valid test results reported divided by the number of collection kits shipped to patients 60 or more days prior to June 30, 2015.

Comprehensive screening program drives compliance

73% Patient Compliance*

Physician orders

Customer outreach

Cologuard completed

Physician provided result

Never screened before Screened with colonscopy only

Screened with colonscopy and FIT/

FOBT

Screened with FIT/FOBT only

36% 36%

Source: Exact Sciences Laboratories LLC data (unpublished), n = 2,997

8% 20%

19

Screening history of Cologuard® users Increasing America’s screening population

v Exact Sciences’ Pipeline

20

Exact Sciences is committed to helping win the war on cancer through

early detection

OUR VISION

21

Exact Sciences is well-positioned to develop a blood-based lung cancer test

Scientific Capabilities Robust chemistry automation platform

Ability to Collaborate Successful collaboration with Mayo Clinic

FDA/CMS Experience Pioneered parallel review with Cologuard®

Clinical Trial Execution 10,000-patient DeeP-C clinical trial

Commercial Capability 200-person primary care sales force

22

221,000 new diagnoses in US

Source: Am Cancer Soc. Cancer Facts & Figures 2015. Atlanta: American Cancer Society; 2015.

Lung Cancer: America’s leading cancer killer

15,590 27,540

40,560 40,730 [VALUE]

158,040

Esophageal Prostate Pancreas Breast Colorectal Lung

Annual US cancer mortality

Lung

23

Low Dose CT (LDCT) screening faces enormous challenges and costs

Limitations to LDCT

Sensitivity 94%

Positives nodules that are benign

96%

Specificity 73%

Often harmful and invasive

~$3,600 per positive result

Radiation exposure

Impact of follow-up

Approved by regulators

24 Sources: N Engl J Med. 2013 May 23;368(21):1980-91. doi: 10.1056/NEJMoa1209120 (National Lung Screening Trial Research Team)

Bringing blood-based tests to large populations

Screening diagnostic for high-risk smokers and

former smokers

Nodules discovered via CT screening or

incidentally

US Patient Population

4M

10M

25

Monitoring US population for nodules will compound annually to reach more than 20M

•  ~4M patients with nodules added annually

= 4M

0

3

6

9

12

15

18

21

24

1 7 Years from Launch

Popu

latio

n (M

)

High follow-up, high positive LDCT attrition

26

27

Financial performance remains strong

Q2 revenues $8.1 million

Q2 operating expense $42.4 million

Q2 end cash balance $210.8 million

July 20, 2015 financial offering $175 million